中国中药杂志

2014, v.39(02) 285-290

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

痰瘀同治方对小型猪冠状动脉粥样硬化炎症反应的影响
Effect of formula of removing both phlegm and blood stasis on inflammatory reaction in Chinese mini-swine with coronary atherosclerosis

任建勋;李磊;林成仁;付建华;马悦颖;李军梅;李鸿海;王敏;刘建勋;
REN Jian-xun;LI Lei;LIN Cheng-ren;FU Jian-hua;MA Yue-ying;LI Jun-mei;LI Hong-hai;WANG Min;LIU Jian-xun;Institute of Basic Medical Sciences of Xiyuan Hospital,China Academy of Chinese Medical Sciences, Beijing Key Laboratory of Chinese Materia Pharmacology;

摘要(Abstract):

目的:观察痰瘀同治方对小型猪冠状动脉动脉粥样硬化炎症反应的抑制作用。方法:将36只中国小型猪随机分为正常对照组,模型组,舒降之组和痰瘀同治方高、中、低剂量组(生药2.0,1.0,0.5 g·kg-1),每组6只;除对照组外,其他各组均给予高脂饲料喂养2周后,采用介入技术球囊损伤冠状动脉左前降支内皮,术后继续高脂饲料喂养8周,制备小型猪冠状动脉粥样硬化模型;术后给药8周,采用血管内超声观察各组动物冠状动脉斑块负荷,进行冠状动脉病理形态学观察,ELISA法测定血清超敏性C反应蛋白(high-sensitivity C-reactive protein,hs-CRP),肿瘤坏死因子(tumor necrosis factor,TNF)-α和白介素(interleukin,IL)-6等炎症因子水平。采用免疫组化的方法观察冠状动脉血管壁NF-κB p65核移位的表达。结果:与对照组比较,模型组动物在实验结束时冠状动脉斑块负荷明显增加(P<0.01),冠状动脉病变血管组织结构改变明显异常,管腔狭窄,出现大量的泡沫细胞以及炎细胞侵润;循环中hs-CRP,TNF-α及IL-6水平均显著升高(P<0.01);免疫组化显示模型组小型猪冠脉NF-κB p65核移位显著增加。与模型组比较,痰瘀同治方能够明显减轻AS斑块负荷(P<0.01),抑制管腔狭窄,减少炎细胞侵润,降低血清hs-CRP,TNF-α和IL-6等炎症细胞因子水平并抑制冠脉NF-κB p65核移位(P<0.05或P<0.01)。结论:痰瘀同治方能够通过控制NF-κB p65核移位而降低下游炎症反应,从而抑制中国小型猪冠状动脉粥样硬化斑块的发生和发展。
Objective: To observe the effect of formula of removing both phlegm and blood stasis( TYTZ) in inhibiting the inflammatory reaction in Chinese mini-swine with coronary atherosclerosis. Method: Totally 36 Chinese mini-swine were randomly divided to six groups: the normal control group,the model group,the Shujiangzhi group and TYTZ groups with does of 2. 0,1. 0 and 0. 5 g ·kg- 1,and six each in every group. Except for the normal control group,all of other groups were fed with high-fat diet for 2 weeks. Interventional balloons are adopted to injure their left anterior descending artery endothelium. After the operation,they were fed with high-fat diet for 8 weeks to prepare the coronary atherosclerosis model. In the 8th week after the operation and administration,the intravascular ultrasound was adopted to observe the coronary artery plaque burden of each group and the pathological morphology of coronary artery. Such inflammatory factors as high-sensitivity C-reactive protein( hs-CRP),tumor necrosis factor( TNF)-α and interleukin( IL)-6 were detected by ELISA. The expression of NF-κB p65 nuclear translocation was observed by the immunohistochemical method. Result: Compared with the normal control group,the model group showed significant increase in the coronary artery plaque burden at the end of the experiment( P < 0. 01),notably abnormal structural changes in atherosclerotic vascular tissues,luminal stenosis,a large number of foam cells and inflammatory cell infiltration,remarkable growth of hs-CRP,TNF-α and IL-6 levels( P < 0. 01). The immunohistochemical staining also showed the significant increase in the NF-κB p65 nuclear translocation of coronary artery of Chinese mini-swine in the model group. Compared with the model group,TYTZ could significantly attenuate atherosclerotic plaque burden( P <0. 01),inhibit the coronary luminal stenosis,reduce inflammatory cell infiltration,decrease such inflammatory cell factors as hsCRP,TNF-α and IL-6 in serum,and inhibit the NF-κB p65 nuclear translocation of coronary artery( P < 0. 05 or P < 0. 01). Conclusion: TYTZ can reduce the downstream inflammatory reaction by controlling NF-κB p65 nuclear translocation,so as to inhibit the occurrence and development of coronary atherosclerotic plaque in Chinese mini-swine.

关键词(KeyWords): 痰瘀同治方;冠状动脉动脉粥样硬化;中国小型猪;炎症
formula of removing both phlegm and blood stasis;coronary atherosclerosis;Chinese mini-swine;inflammation

Abstract:

Keywords:

基金项目(Foundation): 国家“重大新药创制”科技重大专项(2009ZX09502-017,2012ZX09301002-004);; 北京市科技专项;; 中药药理北京市重点实验室2012年阶梯计划项目(z121107002812036)

作者(Authors): 任建勋;李磊;林成仁;付建华;马悦颖;李军梅;李鸿海;王敏;刘建勋;
REN Jian-xun;LI Lei;LIN Cheng-ren;FU Jian-hua;MA Yue-ying;LI Jun-mei;LI Hong-hai;WANG Min;LIU Jian-xun;Institute of Basic Medical Sciences of Xiyuan Hospital,China Academy of Chinese Medical Sciences, Beijing Key Laboratory of Chinese Materia Pharmacology;

参考文献(References):

扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享